Compass Therapeutics Inc (CMPX) Stock Price, Quote & News

Company Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8099

Website: www.compasstherapeutics.com

Address:

80 Guest Street, Suite 601, Boston, United States

Jph85 Feb. 20 at 11:55 AM

$CMPX https://clinicaltrials.gov/study/NCT07419841

0 · Reply

CH_Expat Feb. 19 at 9:32 PM

$CMPX On watch. Interested here.

0 · Reply

dR_HumanEvolution Feb. 14 at 6:42 PM

$ALLO $CMPX $IOVA $PMVP $VSTM

0 · Reply

BioTechHealthX Feb. 14 at 4:15 AM

$CMPX Compass Therapeutics Inc. (NASDAQ: CMPX) has randomized Phase 2/3 traction in aggressive biliary tract cancer and a near-term PFS/OS moment that can re-rate the story fast. With a roughly $1.12B market cap and a runway narrative that reduces dilution fear, CMPX is one of the more catalyst-loaded oncology biotech stocks to watch in 2026. https://biotechhealthx.com/biotech-news/compass-therapeutics-cmpx-has-a-survival-data-trapdoor-and-2026-might-be-when-it-opens/

0 · Reply

BioTechHealthX Feb. 14 at 4:12 AM

$ALLO $VSTM $IOVA $CMPX $PMVP Cancer biotech stocks can stay silent for months—then surge overnight when a trial hits its primary endpoint. Discover the 10 oncology small-caps with catalyst calendars, clinical milestones, and asymmetric upside that could reshape market sentiment in 2026. https://biotechhealthx.com/biotech-news/top-10-cancer-biotech-small-caps-that-could-shock-the-market-next/

0 · Reply

Quantumup Feb. 13 at 3:32 PM

Craig-Hallum🏁 $CMPX ~argues Tovecimig already met the ORR 1° of a Ph3 2L BTC study/ PFS/OS data is expected in Mar—expects these data to support a pot '27 comm launch in 2L BTC (models a $1B peak oppy)—+sees sig⬆️pot from early-stage pipeline. $AZN $ BMY $BNTX $DCTH MRK Here's what else Craig-Hallum said in its initiation report: https://x.com/Quantumup1/status/2022332075974488090?s=20

0 · Reply

notreload_ai Feb. 13 at 2:28 PM

Investment firm Craig-Hallum starts coverage on $CMPX with a Buy rating and $15 price target, highlighting its promising bispecific antibody pipeline and potential blockbuster in biliary tract cancer. https://notreload.xyz/craig-hallum-bullish-on-compass-therapeutics/

0 · Reply

jacksparo Feb. 13 at 1:10 AM

$IBRX $SLS $CMPX $ABOS Regular plus after hours closed! Time to review everything happened in this high volatile day!

0 · Reply

johnwestt2025 Feb. 12 at 2:01 AM

$SLS $CMPX $ALT $GUTS $IBRX Great group I joined it today!

0 · Reply

jacksparo Feb. 11 at 10:00 PM

$SLS $CMPX $ALT $GUTS $IBRX Took too many good notes today. And shared some already in my Special Biotech live telegram group ✅✅! This Friday s lot of options will be expired! We need to pay attention to that also!

1 · Reply

Compass Therapeutics: Exciting Clinical Updates Inbound For 2026

Jan 14, 2026, 1:26 PM EST - 5 weeks ago

Compass Therapeutics, Inc. (CMPX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 6, 2026, 8:00 AM EST - 6 weeks ago

Compass Therapeutics Provides Corporate Update

Jan 5, 2026, 4:30 PM EST - 7 weeks ago

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 5, 2026, 8:00 AM EST - 7 weeks ago

Compass Therapeutics Announces Key Leadership Appointments

Dec 17, 2025, 7:30 AM EST - 2 months ago

Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

Dec 4, 2025, 5:08 PM EST - 2 months ago

Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 4, 2025, 4:48 PM EST - 2 months ago

Compass Therapeutics, Inc. (CMPX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 25, 2025, 8:00 AM EST - 3 months ago

Compass Therapeutics to Participate in Upcoming December Investor Events

Nov 5, 2025, 7:30 AM EST - 3 months ago

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 9:00 AM EST - 3 months ago

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 3, 2025, 8:00 AM EST - 4 months ago

Compass Therapeutics to Participate in Upcoming November Investor Events

Sep 10, 2025, 2:06 AM EDT - 5 months ago

Compass Therapeutics, Inc. (CMPX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 26, 2025, 8:00 AM EDT - 6 months ago

Compass Therapeutics to Participate in Upcoming September Investor Events

Aug 13, 2025, 9:40 AM EDT - 6 months ago

Compass Therapeutics: Finding Their Way With More Positive Updates In BTC

Aug 12, 2025, 10:28 PM EDT - 6 months ago

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

Aug 12, 2025, 4:01 PM EDT - 6 months ago

Compass Therapeutics Announces Proposed Public Offering

Aug 11, 2025, 7:00 AM EDT - 7 months ago

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

Aug 8, 2025, 4:01 PM EDT - 7 months ago

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

May 28, 2025, 8:00 AM EDT - 9 months ago

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 12, 2025, 9:51 PM EDT - 10 months ago

Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers

May 8, 2025, 8:00 AM EDT - 10 months ago

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

May 6, 2025, 8:00 AM EDT - 10 months ago

Compass Therapeutics to Participate in Upcoming May Investor Events

$Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting$

Apr 28, 2025, 8:00 AM EDT - 10 months ago

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Apr 21, 2025, 8:00 AM EDT - 11 months ago

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

Apr 2, 2025, 4:05 PM EDT - 11 months ago

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Apr 1, 2025, 7:00 AM EDT - 11 months ago

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Mar 31, 2025, 4:05 PM EDT - 11 months ago

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Feb 27, 2025, 8:00 AM EST - 1 year ago

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Dec 10, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Dec 9, 2024, 12:54 PM EST - 1 year ago

Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer

Dec 2, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 8:30 AM EST - 1 year ago

Compass Therapeutics to Participate in Upcoming Investor Events

Nov 12, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2024, 10:05 AM EST - 1 year ago

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 4, 2024, 10:31 AM EDT - 1 year ago

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

Jun 20, 2024, 3:14 AM EDT - 1 year ago

Compass Therapeutics: Pointing Right At Some Tough Cancers

May 28, 2024, 4:10 PM EDT - 1 year ago

Compass Therapeutics Announces CEO Transition

May 23, 2024, 5:05 PM EDT - 1 year ago

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

May 14, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Apr 9, 2024, 12:00 PM EDT - 2 years ago

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 21, 2024, 9:00 AM EDT - 2 years ago

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 8:00 AM EST - 2 years ago

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Nov 9, 2023, 7:30 AM EST - 2 years ago

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jun 22, 2023, 4:05 PM EDT - 2 years ago

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

Jph85 Feb. 20 at 11:55 AM

$CMPX https://clinicaltrials.gov/study/NCT07419841

0 · Reply

CH_Expat Feb. 19 at 9:32 PM

$CMPX On watch. Interested here.

0 · Reply

dR_HumanEvolution Feb. 14 at 6:42 PM

$ALLO $CMPX $IOVA $PMVP $VSTM

0 · Reply

BioTechHealthX Feb. 14 at 4:15 AM

0 · Reply

BioTechHealthX Feb. 14 at 4:12 AM

0 · Reply

Quantumup Feb. 13 at 3:32 PM

0 · Reply

notreload_ai Feb. 13 at 2:28 PM

0 · Reply

jacksparo Feb. 13 at 1:10 AM

$IBRX $SLS $CMPX $ABOS Regular plus after hours closed! Time to review everything happened in this high volatile day!

0 · Reply

johnwestt2025 Feb. 12 at 2:01 AM

$SLS $CMPX $ALT $GUTS $IBRX Great group I joined it today!

0 · Reply

jacksparo Feb. 11 at 10:00 PM

1 · Reply

Stewardass Feb. 9 at 4:32 PM

$CMPX added

0 · Reply

BioTechHealthX Feb. 8 at 5:06 PM

$CMPX Compass Therapeutics (NASDAQ:CMPX) is on biotech watchlists as oncology data and upcoming catalysts drive interest. Here’s what investors are watching, why the setup matters, and where risk lives. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-acquire-compass-therapeutics-cmpx-shares/

0 · Reply

UgoGreg Feb. 8 at 2:55 PM

$CMPX https://youtu.be/b4CDDEB3OQo

0 · Reply

Merlintrader Feb. 8 at 7:44 AM

$CMPX https://www.merlintrader.com/compass-therapeutics/

0 · Reply

Quantumup Feb. 4 at 7:53 PM

Canaccord Genuity⬆️ $CMPX's PT to $13 from $10, reiterated at Buy and said, We see upside to $13 and downside to $4 on upcoming Phase 2/3 data for tovecimig + paclitaxel expected end of 1Q26. $BMY $TEVA $SNY $PFE AMGN We see a low bar vs paclitaxel monotherapy, and note Compass demonstrated a statistically significant benefit for response rate. We also believe safety is manageable, with Grade 3+ neutropenia likely lower vs Phase 2. We also benchmarked Progression Free Survival and Overall Survival (OS) against standard of care FOLFOX.

0 · Reply

DividendCrafters Feb. 4 at 2:24 PM

$CMPX is a clinical-stage biotech developing gene therapies; it is a high-risk, early-stage company in the capital-intensive gene therapy sector.

0 · Reply

Cocky_day_trader Feb. 3 at 6:25 PM

$CMPX Tanking Time to pack the bags. Not financial advise

2 · Reply

BillionerOfKing Jan. 30 at 2:11 AM

$CMPX Current Stock Price: $6.37 Contracts to trade: $5 CMPX Feb 20 2026 Call Entry: $1.17 Exit: $1.54 ROI: 31% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

outlawinvestor1 Jan. 29 at 12:57 PM

$SMMT even with fda review (accepted, but not prioritized), i still think there are better bispec onc investment opportunities $BNTX $CMPX $MRK

3 · Reply

Cocky_day_trader Jan. 27 at 11:47 AM

$CMPX wow Bos all time frames

0 · Reply

Bullish_Swagger Jan. 22 at 5:49 PM

$CMPX - Breaking out on all time frames with volume- All time Highs Incoming ! - News ??? 👀

1 · Reply

Rox22 Jan. 15 at 4:41 PM

$CMPX amazing update. https://seekingalpha.com/article/4859816-compass-therapeutics-inc-cmpx-presents-at-44th-annual-j-p-morgan-healthcare-conference

0 · Reply

Market Cap	1.10B
Revenue (ttm)	850,000.00
Net Income (ttm)	-49.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,809.41%
Debt to Equity Ratio	0.00

Volume	1,799,900
Avg Vol	2,156,728
Day's Range	N/A - N/A
Shares Out	177.86M
Stochastic %K	13%
Beta	1.46
Analysts	Strong Sell
Price Target	$13.57